Drug resistant cancers like pancreatic ductal adenocarcinoma (PDAC) are difficult to treat， and nanoparticle drug delivery systems can overcome some of the limitations of conventional systemic chemotherapy. In this study， we demonstrate that FdUMP and dFdCMP， the bioactive， phosphorylated metabolites of the chemotherapy drugs 5-FU and gemcitabine， can be encapsulated into calcium phosphosilicate nanoparticles (CPSNPs). The non-phosphorylated drug analogs were not well encapsulated by CPSNPs， suggesting the phosphate modification is essential for effective encapsulation. In vitro proliferation assays， cell cycle analyses and/or thymidylate synthase inhibition assays verified that CPSNP-encapsulated... More
Drug resistant cancers like pancreatic ductal adenocarcinoma (PDAC) are difficult to treat， and nanoparticle drug delivery systems can overcome some of the limitations of conventional systemic chemotherapy. In this study， we demonstrate that FdUMP and dFdCMP， the bioactive， phosphorylated metabolites of the chemotherapy drugs 5-FU and gemcitabine， can be encapsulated into calcium phosphosilicate nanoparticles (CPSNPs). The non-phosphorylated drug analogs were not well encapsulated by CPSNPs， suggesting the phosphate modification is essential for effective encapsulation. In vitro proliferation assays， cell cycle analyses and/or thymidylate synthase inhibition assays verified that CPSNP-encapsulated phospho-drugs retained biological activity. Analysis of orthotopic tumors from mice treated systemically with tumor-targeted FdUMP-CPSNPs confirmed the in vivo up take of these particles by PDAC tumor cells and release of active drug cargos intracellularly. These findings demonstrate a novel methodology to efficiently encapsulate chemotherapeutic agents into the CPSNPs and to effectively deliver them to pancreatic tumor cells.
